Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TCMs Not Paxlovid Gain Traction As Beijing On High Alert

But WHO Cautious On Findings

Executive Summary

As Shanghai enters a second week of a city-wide lockdown with no signs of policy easing, officials are promoting the use of traditional Chinese medicines rather than Pfizer's recently approved Paxlovid.

You may also be interested in...



Curious Case Of LHQW: Behind The TCM Central To China’s COVID Zero Policies

The role of a traditional Chinese medicine provided to the general public in China to fend off COVID-19 is controversial given limited evidence and even misleading, some say.

US Toning Down China CDMO Tension But New Restrictions Emerge

The latest developments in a US Congressional draft bill to curb Chinese biotech operations in the US is separating contract manufacturing and research from gene sequencing service providers, which may give China's major contract players reasons to breathe easy. 

China HPV Demand Shaping Merck But Competitors Catching Up

Multiple factors were behind Merck & Co’s rise to ace AstraZeneca and others to become the leading pharma multinational in the world’s second-largest pharma market in 2023, including partnerships and competition and a strong position in the growing HPV vaccine sector.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC146200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel